Home › Employers › Dendreon Pharmaceuticals LLC
Dendreon Pharmaceuticals LLC: H-1B salaries and sponsorship
Dendreon Pharmaceuticals LLC filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $105,462.
Does Dendreon Pharmaceuticals LLC sponsor H-1B visas?
Dendreon Pharmaceuticals LLC filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Apr 7, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Senior Computational Biologist I | 1 | $105,462 |
| Financial Specialist | 1 | $52,707 |
| Senior Computational Biology Analyst | 1 | $116,357 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 1 | $105,462 |
| FY2025 | 1 | $52,707 |
| FY2026 | 1 | $116,357 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Senior Computational Biology Analyst | $116,357–$174,535 Level I | Seattle, WA | Apr 7, 2026 | Apr 19, 2026 | Certified |
| Financial Specialist | $52,707–$64,896 Level I | Seal Beach, CA | May 23, 2025 | Oct 1, 2025 | Certified |
| Senior Computational Biologist I | $105,462–$158,192 Level III | Seattle, WA | Mar 16, 2023 | Apr 19, 2023 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).